The low risk of causing hypoglycaemia for metformin, DPP-4 inhibitors, GLP-1-Ras, and SGLT-2 inhibitors indicates that these antidiabetic drugs might be used for treatment of people with type 2 diabetes undertaking TRE regimens without major safety concerns. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.